TICKERNERD
Menu
PYXSPYXSHealthcare · Biotechnology

PYXS Stock Forecast: Pyxis Oncology, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.20
−2.29% on the day

The 10 Wall Street analysts covering Pyxis Oncology, Inc. hold a median 12-month price target of $7 — +119.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$266.5M
Ticker Nerd rank
80 / 100
Median analyst target
$7.00
Analysts covering
10
Revenue$0.0−100.0% y/y
Operating income−$26.0M
Net income−$25.3M
Free cash flow−$18.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.4%
1M
+12.9%
YTD
+177.8%
1Y
+71.8%
From 52W high
−40.2%
From 52W low
+201.4%
$1.06
$5.34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PYXS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pyxis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Momentum
83
Growth
81
Value
68
Issuance
67
Size
64
Revisions
50
Quality
35
Volatility
24

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (24): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PYXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PYXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26PYXSHigh $19.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $6.00Median $7.00High $19.00

The green dot is the last close — the median target sits +119.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.MaintainsBuy$7.00 → $8.00
10 Sept 2026WedbushMaintainsOutperform$6.00 → $8.00
9 Sept 2026Wells FargoMaintainsOverweight$12 → $19
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$7.00
18 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026Wells FargoInitiatesOverweight$12
3 Aug 2026Wells FargoInitiatesOverweight—
2 July 2026Leerink PartnersMaintainsOutperform$9.00 → $7.00
2 July 2026Leerink PartnersMaintainsOutperform—
5 May 2026WedbushInitiatesOutperform—
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Mar 2026StifelMaintainsBuy—
19 Dec 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2025RBC CapitalMaintainsOutperform—
24 Nov 2025Stephens & Co.MaintainsOverweight—
4 Nov 2025GuggenheimMaintainsBuy—
4 Sept 2025GuggenheimInitiatesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PYXS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PYXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Pyxis Oncology, Inc. returned +71.8% against +17.5% for the S&P 500, dividends included.

PYXS vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Oct 25Jan 26Apr 26Jul 26PYXSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PYXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
5
Fundamentals

Pyxis Oncology, Inc. (PYXS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 86% of US stocks

Price / sales
24.3×

Cheaper than 8% of US stocks

Price / book
17.8×

Cheaper than 5% of US stocks

EV / EBITDA
−3.0×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−812.7%

Higher than 6% of US stocks

Net margin
82.8%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−179.1%

Higher than 8% of US stocks

Return on assets
−63.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pyxis Oncology, Inc. (PYXS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pyxis Oncology, Inc. has a market value of $266.5M and an enterprise value of $252.6M.

  • Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$88.7M, a −803.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$67.9M.

  • Shares outstanding: 63.4M.

  • Trailing P/E: −2.5×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Pyxis Oncology, Inc. employs 56 people — $197K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

PYXS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PYXSPyxis Oncology, Inc.$266.5M
80
ALXOALX Oncology Holdings, Inc.$268.3M
62
FATEFate Therapeutics, Inc.$268.6M
94
CAMPCAMP4 Therapeutics Corp.$266.7M
65
TRDAEntrada Therapeutics, Inc.$264.0M
54
ACIUAC Immune SA$273.1M
35
IMRXImmuneering Corp.$275.7M
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pyxis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PYXS news & analysis

Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript

Seeking Alpha · 10 Sept 2026neutral

Pyxis Oncology discussed its MICVO monotherapy Phase I clinical data in head and neck squamous cell carcinoma during a presentation transcript. The item shares this discussion as published by Seeking Alpha.

Why it matters — PYXS watchers would follow this as an update on the company's early-stage clinical program for MICVO in HNSCC.

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

Benzinga · 9 Sept 2026negative

Pyxis Oncology shared updated data from its Phase 1 trial of micvotabart pelidotin (MICVO) on Wednesday. An analyst flagged key safety liabilities associated with the cancer drug.

Why it matters — The safety liabilities highlighted by the analyst could affect how PYXS watchers assess the clinical profile and risk related to micvotabart pelidotin.

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

GlobeNewsWire · 9 Sept 2026positive

Pyxis Oncology announced positive updated data from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. The data showed a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months, and 79% 12-month overall survival probability, with no new safety signals observed.

Why it matters — The promising efficacy and safety results support advancing MICVO into a pivotal Phase 3 program (Headliner trial) planned for mid-2027, positioning the drug as a potential treatment option addressing an unmet need in the HNSCC space.

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

GlobeNewsWire · 8 Sept 2026neutral

Pyxis Oncology announced it will host a live webcast on September 9, 2026 at 7:30 a.m. to present updated data from its Phase 1 monotherapy study of Micvotabart Pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC).

Why it matters — The webcast will provide updated clinical data on MICVO, a key investigational therapy in Pyxis Oncology's pipeline for difficult-to-treat cancers.

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

GlobeNewsWire · 8 Sept 2026neutral

Pyxis Oncology announced that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. John Flavin, Co-Founder and Founding Chairman, will serve as Lead Independent Director, with the leadership transition reflecting the company's continued focus on advancing MICVO through key clinical milestones.

Why it matters — A PYXS watcher would care because a new CEO and Chairman signals a leadership transition at the company while it continues advancing its lead candidate MICVO through clinical milestones.

FAQ

Frequently asked questions about PYXS stock

What is the PYXS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Pyxis Oncology, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PYXS stock a buy right now?

Of the 10 analysts covering Pyxis Oncology, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pyxis Oncology, Inc. 80 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PYXS?

As at 12 Sept 2026, Pyxis Oncology, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will PYXS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +119.1% from the last close, and Ticker Nerd's factor model ranks Pyxis Oncology, Inc. 80 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PYXS stock forecast for 2030?

No analyst covering Pyxis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $19 over the next 12 months.

How has PYXS stock performed over the past year?

Pyxis Oncology, Inc. returned +71.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pyxis Oncology, Inc. do?

Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors.

What is the latest news on PYXS?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript". Pyxis Oncology discussed its MICVO monotherapy Phase I clinical data in head and neck squamous cell carcinoma during a presentation transcript. The item shares this discussion as published by Seeking Alpha.

Company

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer. Its lead programs include micvotabart pelidotin, an investigational antibody-drug conjugate, along with additional candidates such as PYX-106 and PYX-107 that explore different mechanisms for targeting advanced cancers. Pyxis Oncology works across oncology research, clinical development, and translational medicine to advance product candidates intended for patients with limited treatment options. Headquartered in Boston, Massachusetts, Pyxis Oncology operates as part of the biotechnology sector and contributes to the broader development of precision cancer therapeutics.

CEO Mr. Thomas Civik · 56 employees · United States · https://www.pyxisoncology.com